Key Development A new report from UNAIDS warns that the global response to HIV is entering a critical phase after... Read more
Tag: #GlobalTrends
NOVARTIS’ PATENT CLIFF DEEPENS WITH 322 MORE LAYOFFS AND FOUR WORKFORCE REDUCTIONS IN FIVE MONTHS
Key Development Novartis has announced another workforce reduction, eliminating 322 positions at its East Hanover, New Jersey headquarters, according to... Read more
ASTRAZENECA BETS ON CHINA TO STRENGTHEN ITS RESPIRATORY PIPELINE
Key Development AstraZeneca has committed up to $2.1 billion in a global licensing agreement with China's Sino Biopharmaceutical for TQC3721,... Read more
ASTRAZENECA’S $1.9B CHINA BET: WHY RESPIRATORY INNOVATION IS BECOMING BIG PHARMA’S NEXT BATTLEGROUND
Key Development AstraZeneca has expanded its strategic partnership with China’s pharmaceutical sector through a licensing agreement with Sino Biopharmaceutical worth... Read more
VERTEX’S $10 BILLION BET ON CRINETICS SIGNALS THE NEXT PHASE OF RARE DISEASE CONSOLIDATION
Key Development Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately US$10 billion, marking one... Read more
Europe Moves Bispecific Antibodies Earlier in Follicular Lymphoma Care as AbbVie Secures New Regulatory Milestone
Key Development The European Commission has approved AbbVie and Genmab's bispecific antibody TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab... Read more






